Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Schultz to head CDRH for rest of 2004?

This article was originally published in The Gray Sheet

Executive Summary

Device center medical deputy post unlikely to be filled until CDRH obtains a permanent director, according to FDA staff. The agency had previously suggested that a medical deputy appointment was imminent, and that more than 20 candidates were under review (1"The Gray Sheet" April 19, 2004, p. 3). With the April 30 departure of former CDRH director David Feigal, however, staffers say Dan Schultz could remain acting director through the November elections...

You may also be interested in...



CDRH Leadership Changes May Be Imminent; NCI’s Ellen Feigal To Leave Institute

FDA is vetting a list of more than 20 candidates for a CDRH clinical deputy spot - a position that may grow in stature with the potential departure of Director David Feigal

Changes To EU Pharma Reform: More Questions Than Answers?

In the first of a series of articles on the future direction of the EU pharmaceutical reform proposals, the Pink Sheet looks at the new uncertainties created for the drug industry after the European Parliament voted through a series of amendments in the area of regulatory data protection.

Probiotics And Cold Remedies Boost Recordati In 2023

Italy's Recordati saw its OTC sales grow by 10% in 2023 driven by the recovery of the cough & cold market and a growing demand for probiotics.

Latest Headlines
See All
UsernamePublicRestriction

Register

MT020443

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel